GVHD prophylaxis with post-transplant cyclophosphamide results in lower incidence of GVHD and allows faster immunosuppressive treatment reduction compared to antithymocyte globulin in 10/10 HLA-matched unrelated allogeneic hematopoietic cell transplantation

MeSH terms

• Antilymphocyte Serum / therapeutic use
• Cyclophosphamide / therapeutic use
• Graft vs Host Disease* / etiology
• Hematopoietic Stem Cell Transplantation* / methods
• Humans
• Immunosuppressive Agents / therapeutic use
• Incidence
• Retrospective Studies
• Unrelated Donors